U.S. Healthcare professionals can access a new novel NAD+ blood diagnostic for their patients, following a new partnership between epigenetic laboratory TruDiagnostic and Finland-based NAD diagnostic company NADMED.
NAD+/NADH is a metabolite with a significant relationship to aging and many other diseases. Abnormal levels of these metabolites have been linked to improper immune function; metabolic disease; dementia and neurodegeneration; heart disease; and more. NAD+/NADH is essential to sustaining optimal function, and levels in your body markedly decline with age.
TruDiagnostic decided to partner with NADMED for their test accuracy and reliability, the companies say. The Q-NADMED Blood Kit is CE-marked for measuring NAD+ and NADH from a small blood sample for a range of clinical purposes. The Q-NADMED Blood Kit is the only method for the NAD measurement to have received a CE-marking. This high level of reliability is consistent with the internal standard of TruDiagnostic.
“We appreciate TruDiagnostic’s agile, yet diligent approach to introducing a novel technology to their customers in the US market. We foresee a fruitful cooperation to continuously develop business and service models to meet the needs for NAD testing of the varied customer base,” says Jari Närhi, NADMED CEO and Co-Founder.
Additional competitive advantages for NADMED rest in the extraction technique, which is simple and robust, and works with blood samples; and a quick and reliable detection method. Another advantage of NADMED testing kits is that it allows accurate, quantitative detection of metabolites in a sample due to know-how regarding preparation and preservation of NAD standards used in the kit.
Featured image: New NAD+ test kit by TruDiagnostic and NADMED for U.S. healthcare providers. Photo: TruDiagnostic
